Document is current
Any future updates will be listed below
-
Authors
Shadman, Mazyar https://orcid.org/0000-0002-3365-6562
Ahn, Kwang W.
Kaur, Manmeet
Lekakis, Lazaros
Beitinjaneh, Amer
Iqbal, Madiha https://orcid.org/0000-0001-6752-5440
Ahmed, Nausheen https://orcid.org/0000-0003-4336-4982
Hill, Brian
Hossain, Nasheed M.
Riedell, Peter https://orcid.org/0000-0003-2719-0580
Gopal, Ajay K.
Grover, Natalie https://orcid.org/0000-0002-1346-3157
Frigault, Matthew
Brammer, Jonathan
Ghosh, Nilanjan https://orcid.org/0000-0002-3848-6136
Merryman, Reid https://orcid.org/0000-0002-6360-3234
Lazaryan, Aleksandr https://orcid.org/0000-0001-9605-6436
Ram, Ron
Hertzberg, Mark https://orcid.org/0000-0001-8495-4669
Savani, Bipin https://orcid.org/0000-0002-3304-9965
Awan, Farrukh
Khimani, Farhad
Ahmed, Sairah https://orcid.org/0000-0001-7302-8299
Kenkre, Vaishalee P.
Ulrickson, Matthew https://orcid.org/0000-0002-1458-7813
Shah, Nirav https://orcid.org/0000-0002-4336-1071
Kharfan-Dabaja, Mohamed A. https://orcid.org/0000-0001-7394-5185
Herrera, Alex
Sauter, Craig
Hamadani, Mehdi https://orcid.org/0000-0001-5372-510X
- License Information
-
More Information
Article History
Received: 1 April 2024
Revised: 24 May 2024
Accepted: 13 June 2024
First Online: 8 July 2024
Competing interests
: Mazyar Shadman reports Consulting, Advisory Boards, steering committees or data safety monitoring committees: Abbvie, Genentech, AstraZeneca, Janssen, Beigene, Bristol Myers Squibb, Morphosys/Incyte, Kite Pharma, Eli Lilly, Mustang Bio, Fate therapeutics, Nurix, Merck. Research Funding: Mustang Bio, Genentech, AbbVie, Beigene, AstraZeneca, Genmab, Morphosys/Incyte, Vincerx .Stock options: Koi Biotherapeutics. Employment: Bristol Myers Squibb (spouse). Peter Riedell has served as a consultant and/or advisory board member for AbbVie, Novartis, BMS, ADC Therapeutics, Kite/Gilead, Sana Biotechnology, Nektar Therapeutics, Nurix Therapeutics, Intellia Therapeutics, CVS Caremark, Genmab, BeiGene, Janssen, and Pharmacyclics. He has received honoraria from Novartis. Research support from BMS, Kite Pharma, Novartis, MorphoSys, CRISPR Therapeutics, Calibr, Xencor, Fate Therapeutics, AstraZeneca, Genentech, and Tessa Therapeutics. Ajay K. Gopal. Research Funding: Merck, I-Mab bio, IgM Bio, Takeda, Gilead, Astra-Zeneca, Agios, Janssen, BMS, SeaGen, Teva, Genmab. Consultancy/Honoraria: Incyte, Kite, Morphosys/Incyte, ADCT, Acrotech, Merck, Karyopharm, Servier, Beigene, Cellectar, Janssen, SeaGen, Epizyme, I-Mab bio, Gilead, Genentech, Lilly, Caribou, Fresenius-Kabi, Scitek. Stock Options: Compliment Corporation. Matthew J Frigault repots consulting and advisory roles for Kite/Gilead, BMS, Novartis, JnJ/Legend. Research funding from Arcellx, Kite/Gilead, Novartis, Incyte. Jonathan Brammer receives research funding from BMS, Incyte and consulting fee from DrenBio, Kymera. Reid Merryman: Advisory board: Genmab, Adaptive Biotechnologies, Bristol Myers Squibb, Abbvie, Inteillia, Epizyme.Consulting: Alphasights, DG Medicine.Institutional research funding: Merck, Bristol Myers Squibb, Genmab, Genentech/Roche. Aleksandr Lazaryan : Consultancy, honoraria, scientific advisory board: Sanofi. Ron Ram: Honoraria: Novartis, Gilead, Takeda, BMS, MSD, Sanofi. Mark Hertzberg: Advisory/honoraria for the following: Takeda, Janssen, Roche, Otsuka, Beigene, Gilead. Farrukh Awan has provided consultancy to: Genentech, Astrazeneca, Abbvie, Janssen, Pharmacyclics, Gilead sciences, Kite pharma, <u>Celgene</u>, Karyopharm, MEI Pharma, Verastem, Incyte, Beigene, Johnson and Johnson, Dava Oncology, BMS, Merck, Cardinal Health, ADCT therapeutics, Epizyme, Caribou Biosciences, Cellecter Bisosciences, Loxo Oncology, Adaptive Biotechnologies and received research funding from Pharmacyclics. Nirav Shah reports participation on advisory boards and/or consultancy for Kite Pharma, BMS-Juno, Miltenyi Biotec, Lilly Oncology, Epizyme, Incyte, Novartis, Seattle Genetics, Abbvie, and Galapagos. He has research funding, travel support, and honoraria from Lilly Oncology and Miltenyi Biotec. In addition, N.S. is on a scientific advisory board for Tundra Therapeutics. Mohamed A. Kharfan-Dabaja : Research/grant from Novartis, BMS and Pharmacyclics. Alex F. Herrera received research funding and consultancy from Bristol Myers Squibb, Genentech, Merck, Seattle Genetics, AstraZeneca, ADC Therapeutics. Research finding from KiTE Pharma and Gilead Sciences and consultancy from Karyopharm, Takeda, Tubulis, Regeneron, Genmab, Pfizer, Caribou Biosciences, Adicet Bio, Abbvie, Allogene Therapeutics Craig Sauter has served as a paid consultant for: Kite/a Gilead Company, Celgene/BMS, Gamida Cell, Karyopharm Therapeutics, Ono Pharmaceuticals, MorphoSys, CSL Behring, Syncopation Life Sciences, CRISPR Therapeutics and GSK. He has received research funds for clinical trials from: Juno Therapeutics, Celgene/BMS, Bristol-Myers Squibb, Precision Biosciences, Actinium Pharmaceuticals, Sanofi-Genzyme, Cargo Therapeutics, Affimed and NKARTA. Mehdi Hamadani reports research support/Funding: Takeda Pharmaceutical Company; ADC Therapeutics; Spectrum Pharmaceuticals; Astellas Pharma. Consultancy: ADC Therapeutics, Omeros, CRISPR, BMS, Kite, Abbvie, Caribou, Genmab. Speaker’s Bureau: ADC Therapeutics, AstraZeneca, BeiGene, Kite. DMC: Inc, Genentech, Myeloid Therapeutics, CRISPR. Other authors did not report a COI.
: All patients included in this analysis have provided written consent for research. The Institutional Review Board of MCW have approved this study. Ethics committee approval is not applicable to this study.
